Search Results - "Calverley, Peter MA"

Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations by Calverley, Peter MA, Prof, Albert, Paul, MD, Walker, Paul P, MD

“…Summary The change in forced expiratory volume in 1 s (FEV1 ) after administration of a short-acting bronchodilator has been widely used to identify patients…”
Get full text

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials by Calverley, Peter MA, Prof, Rabe, Klaus F, Prof, Goehring, Udo-Michael, MD, Kristiansen, Søren, PhD, Fabbri, Leonardo M, Prof, Martinez, Fernando J, Prof

“…Summary Background The phosphodiesterase-4 inhibitor roflumilast can improve lung function and prevent exacerbations in certain patients with chronic…”
Get full text

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change by Jones, Paul W, Anderson, Julie A, Calverley, Peter Ma, Celli, Bartolome R, Ferguson, Gary T, Jenkins, Christine, Yates, Julie C, Vestbo, Jørgen, Spencer, Michael D

“…Little is known about factors that determine health status decline in clinical trials of COPD. To examine health status changes over 3 years in the TORCH study…”
Get full text

What have we learned from large drug treatment trials in COPD? by Calverley, Peter MA, MD, Rennard, Stephen I, Prof

“…Summary Although the development of effective treatments for patients with chronic obstructive pulmonary disease (COPD) has not been seen as a high priority,…”
Get full text

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials by Fabbri, Leonardo M, Prof, Calverley, Peter MA, Prof, Izquierdo-Alonso, José Luis, MD, Bundschuh, Daniela S, PhD, Brose, Manja, MSc, Martinez, Fernando J, Prof, Rabe, Klaus F, Prof

“…Summary Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The efficacy and safety of the…”
Get full text

Characterisation of COPD heterogeneity in the ECLIPSE cohort by Agusti, Alvar, Calverley, Peter M A, Celli, Bartolome, Coxson, Harvey O, Edwards, Lisa D, Lomas, David A, MacNee, William, Miller, Bruce E, Rennard, Steve, Silverman, Edwin K, Tal-Singer, Ruth, Wouters, Emiel, Yates, Julie C, Vestbo, Jørgen

“…Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-pulmonary manifestations. This study describes the heterogeneity…”
Get full text

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD by Rennard, Stephen I, Calverley, Peter M A, Goehring, Udo M, Bredenbröker, Dirk, Martinez, Fernando J

“…As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy…”
Get full text

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials by Dransfield, Mark T, MD, Bourbeau, Jean, MD, Jones, Paul W, Prof, Hanania, Nicola A, MD, Mahler, Donald A, Prof, Vestbo, Jørgen, Prof, Wachtel, Andrew, MD, Martinez, Fernando J, MD, Barnhart, Frank, DVM, Sanford, Lisa, MSc, Lettis, Sally, PhD, Crim, Courtney, MD, Calverley, Peter MA, Prof

“…Summary Background Whether the combination of a once-daily inhaled corticosteroid with a once-daily longacting β2 agonist is more protective than a once-daily…”
Get full text

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study by Jenkins, Christine R, Jones, Paul W, Calverley, Peter M A, Celli, Bartolome, Anderson, Julie A, Ferguson, Gary T, Yates, Julie C, Willits, Lisa R, Vestbo, Jörgen

“…The efficacy of inhaled salmeterol plus fluticasone propionate (SFC) in patients with severe or very severe COPD is well documented. However, there are only…”
Get full text

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study by Coxson, Harvey O, PhD, Dirksen, Asger, DrMedSc, Edwards, Lisa D, PhD, Yates, Julie C, BS, Agusti, Alvar, MD, Bakke, Per, PhD, Calverley, Peter MA, MD, Celli, Bartolome, MD, Crim, Courtney, MD, Duvoix, Annelyse, PhD, Fauerbach, Paola Nasute, MD, Lomas, David A, MD, MacNee, William, MD, Mayer, Ruth J, PhD, Miller, Bruce E, PhD, Müller, Nestor L, MD, Rennard, Stephen I, MD, Silverman, Edwin K, MD, Tal-Singer, Ruth, PhD, Wouters, Emiel FM, MD, Vestbo, Jørgen, DrMedSc

“…Summary Background Emphysema is a key contributor to airflow limitation in chronic obstructive pulmonary disease (COPD) and can be quantified using CT…”
Get full text

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data by Sin, Don D, Dr, Tashkin, Donald, Prof, Zhang, Xuekui, MSc, Radner, Finn, PhD, Sjöbring, Ulf, MD, Thorén, Anders, MD, Calverley, Peter MA, Prof, Rennard, Stephen I, Prof

“…Summary Background Concern is continuing about increased risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD) who use inhaled…”
Get full text

One-year treatment with mometasone furoate in chronic obstructive pulmonary disease by Calverley, Peter M A, Rennard, Stephen, Nelson, Harold S, Karpel, Jill P, Abbate, Eduardo H, Stryszak, Paul, Staudinger, Heribert

“…Many patients with chronic obstructive pulmonary disease (COPD) are treated with twice daily (BID) inhaled corticosteroids (ICS). This study evaluated whether…”
Get full text

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline by Wedzicha, Ers Co-Chair, Jadwiga A, Miravitlles, Marc, Hurst, John R, Calverley, Peter M A, Albert, Richard K, Anzueto, Antonio, Criner, Gerard J, Papi, Alberto, Rabe, Klaus F, Rigau, David, Sliwinski, Pawel, Tonia, Thomy, Vestbo, Jørgen, Wilson, Kevin C, Krishnan, Ats Co-Chair, Jerry A

“…This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations.Comprehensive evidence syntheses,…”
Get full text

Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis by Bafadhel, Mona, Davies, Lisa, Calverley, Peter M A, Aaron, Shawn D, Brightling, Christopher E, Pavord, Ian D

Get full text

Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD by Magnussen, Helgo, Disse, Bernd, Rodriguez-Roisin, Roberto, Kirsten, Anne, Watz, Henrik, Tetzlaff, Kay, Towse, Lesley, Finnigan, Helen, Dahl, Ronald, Decramer, Marc, Chanez, Pascal, Wouters, Emiel F.M, Calverley, Peter M.A

“…In patients with severe COPD receiving inhaled glucocorticoids and two classes of long-acting bronchodilators, glucocorticoid withdrawal was noninferior to…”
Get full text

Changes in Forced Expiratory Volume in 1 Second over Time in COPD by Vestbo, Jørgen, Edwards, Lisa D, Scanlon, Paul D, Yates, Julie C, Agusti, Alvar, Bakke, Per, Calverley, Peter M.A, Celli, Bartolome, Coxson, Harvey O, Crim, Courtney, Lomas, David A, MacNee, William, Miller, Bruce E, Silverman, Edwin K, Tal-Singer, Ruth, Wouters, Emiel, Rennard, Stephen I

“…In patients with chronic obstructive pulmonary disease (COPD), lung function decreases rapidly. Analysis of data from a large observational study of COPD…”
Get full text

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline by Wedzicha, Jadwiga A, Calverley, Peter M A, Albert, Richard K, Anzueto, Antonio, Criner, Gerard J, Hurst, John R, Miravitlles, Marc, Papi, Alberto, Rabe, Klaus F, Rigau, David, Sliwinski, Pawel, Tonia, Thomy, Vestbo, Jørgen, Wilson, Kevin C, Krishnan, Jerry A

“…This document provides clinical recommendations for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It represents a collaborative…”
Get full text

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study by Dal Negro, Roberto W, Wedzicha, Jadwiga A, Iversen, Martin, Fontana, Giovanni, Page, Clive, Cicero, Arrigo F, Pozzi, Edoardo, Calverley, Peter M A

“…Oxidative stress contributes to chronic obstructive pulmonary disease (COPD) exacerbations and antioxidants can decrease exacerbation rates, although we lack…”
Get full text

Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease by Calverley, Peter M.A, Anderson, Julie A, Celli, Bartolome, Ferguson, Gary T, Jenkins, Christine, Jones, Paul W, Yates, Julie C, Vestbo, Jørgen

“…This trial involving more than 6000 patients with chronic obstructive pulmonary disease (COPD) compared the effects on all-cause mortality of treatment with an…”
Get full text

Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort by Miller, Joy, Edwards, Lisa D, Agustí, Alvar, Bakke, Per, Calverley, Peter M.A, Celli, Bartolome, Coxson, Harvey O, Crim, Courtney, Lomas, David A, Miller, Bruce E, Rennard, Steve, Silverman, Edwin K, Tal-Singer, Ruth, Vestbo, Jørgen, Wouters, Emiel, Yates, Julie C, MacNee, William

“…Summary Comorbidities, are common in COPD, have been associated with poor outcomes and are thought to relate to systemic inflammation. To investigate…”
Get full text